Annual report pursuant to Section 13 and 15(d)


12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory is comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard® Nerve Protector, Axoguard® Nerve Cap, Avive® Soft Tissue Membrane, Acroval® Neurosensory and Motor Testing System, Axotouch® Two-Point Discriminator and supplies and is valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:
December 31,
December 31,
Finished goods $ 8,876  $ 10,403 
Work in process 751  730 
Raw materials 2,902  2,728 
Inventory $ 12,529  $ 13,861 

The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes-down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. For the years ended December 31, 2020, 2019 and 2018, the Company had recorded a provision for inventory write-downs of $2,242, $1,887 and $1,343, respectively, primarily relating to product expiration.